DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» Paraxanthine
Paraxanthine
Wo 2010/075090 A2
Methylxanthines and Neurodegenerative Diseases: an Update
Comparison of Caffeine and D-Amphetamine in Cocaine-Dependent Subjects: Differential Outcomes on Subjective and Cardiovascular Effects, Reward Learning, and Salivary
(12) Patent Application Publication (10) Pub. No.: US 2011/0142957 A1 VAN KEMPEN (43) Pub
The Transcriptional Repressor Orphan Nuclear Receptor TLX Is Responsive to Caffeine and Istradefylline
US 2002/0103350 A1 Lyles (43) Pub
Simultaneous Quantification of Antioxidants Paraxanthine
Download Product Insert (PDF)
A Complex but Promising Therapeutic Target for Alzheimer's Disease
2021 Equine Prohibited Substances List
A Non-Imaging High Throughput Approach to Chemical Library Screening at the Unmodified Adenosine-A3 Receptor in Living Cells
FEI Prohibited Substances List
NIH Public Access Author Manuscript Pharmacol Ther
(12) United States Patent (10) Patent No.: US 7,893,070 B2 Van Kempen (45) Date of Patent: Feb
Saliva: a Reliable Sample Matrix in Bioanalytics
Identification of Paraxanthine As the Most Potent Inhibitor of TGF-Β
Involvement of Adenosine A1 and A2A Receptors in the Motor Effects of Caffeine After Its Acute and Chronic Administration
Caffeine Exacerbates Postictal Hypoxia
Top View
Adenosine A2A Receptor Antagonists As Novel Anti-Parkinsonian Agents: a Review of Structure-Activity Relationships
RESPIRATORY ACTIVITY in MEDULLA OBLONGATA and Its Modulation by ADENOSINE and OPIOIDS
Theophylline Assay Preservatives, and Stabilizers
FEI Prohibited Substances List the 2011 List of FEI Prohibited Substances Will Come Into Effect on 4 April 2011
Therapeutic Class Overview Short-Acting Opioids
Comparative Pharmacokinetics of Caffeine and Its Primary Demethylated Metabolites Paraxanthine, Theobromine and Theophylline in Man
The Possible Actions of Methylxanthines on Various Tissues
Pharmacological Potential of Methylxanthines: Retrospective Analysis and Future Expectations
Annual Report
Scientific Background
2015 Report on Prohibited Substances
Extract from the Clinical Evaluation Report for Armodafinil
Caffeine Has Grown
Array-Based Sensing of Purine Derivatives with Fluorescence Dyes
Transient Inhibition of Astrocytogenesis in Developing Mouse Brain Following Postnatal Caffeine Exposure
A Comprehensive Overview of Edcs and Ppcps in Water
Maternal Caffeine Intake Has Minor Effects on Adenosine Receptor Ontogeny in the Rat Brain
1 510(K) SUBSTANTIAL EQUIVALENCE DETERMINATION
Electronic Supplementary Information
The Effect of Voluntary Binge Caffeine and Ethanol Coexposure On
2014 Report on Prohibited Substances
Paraxanthine, the Primary Metabolite of Caffeine Provides Protection Against Dopaminergic Cell Death Via Stimulation of Ryanodine Receptor Channels
Zebrafish Embryo As an in Vivo Model for Behavioral and Pharmacological
Recent Developments in Adenosine Receptor Ligands and Their Potential As Novel Drugs☆
Therapeutic Drug Monitoring of Serum Theophylline Offers a Potential Diagnostic Biomarker of Parkinson’S Disease
Validation of an LC-MS/MS Method for the Quantification of Caffeine And
WO 2017/033032 Al 2 March 2017 (02.03.2017) P O P C T
Serum Caffeine and Metabolites Are Reliable Biomarkers of Early Parkinson Disease Motoki Fujimaki, Shinji Saiki, Yuanzhe Li, Et Al
Role of the Catecholamine and Limbic Systems in Narcolepsy/Cataplexy
The Stimulatory Action and the Development of Tolerance to Caffeine Is Associated with Alterations in Gene Expression in Specific Brain Regions
Known Bioactive Library: LOPAC 1
Thesis Has Been Carried out in the School of Pharmacy and Pharmacology, Under the Supervision of Dr Michael D